butylscopolammonium bromide has been researched along with naloxone in 3 studies
Studies (butylscopolammonium bromide) | Trials (butylscopolammonium bromide) | Recent Studies (post-2010) (butylscopolammonium bromide) | Studies (naloxone) | Trials (naloxone) | Recent Studies (post-2010) (naloxone) |
---|---|---|---|---|---|
695 | 165 | 149 | 20,134 | 1,257 | 3,321 |
Protein | Taxonomy | butylscopolammonium bromide (IC50) | naloxone (IC50) |
---|---|---|---|
Cytochrome P450 2D6 | Homo sapiens (human) | 2 | |
Delta-type opioid receptor | Mus musculus (house mouse) | 0.043 | |
Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0219 | |
Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
Mu-type opioid receptor | Homo sapiens (human) | 0.0397 | |
Delta-type opioid receptor | Homo sapiens (human) | 0.1896 | |
Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.05 | |
Kappa-type opioid receptor | Homo sapiens (human) | 0.0795 | |
Mu-type opioid receptor | Mus musculus (house mouse) | 0.0154 | |
Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0089 | |
Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.0055 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Betti, R; Casanueva, F; Cocchi, D; Frigerio, C; Mantegazza, P; Müller, EE | 1 |
3 other study(ies) available for butylscopolammonium bromide and naloxone
Article | Year |
---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Growth hormone-releasing effect of an enkephalin analog in the dog: evidence for cholinergic mediation.
Topics: Acetylcholine; Animals; Atropine; Butylscopolammonium Bromide; D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; Dogs; Endorphins; Enkephalin, Methionine; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Hormones; Kinetics; Male; Naloxone; Physostigmine; Pimozide; Receptors, Muscarinic | 1980 |